Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

8 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Eligibility Collecting Duct Carcinoma (Kidney) NCT02363751

- 01/03/19 - 1 modulo, 2 itemgroups, 42 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Gemcitabine+Platinium Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (BEVABEL); ODM derived from: https://clinicaltrials.gov/show/NCT02363751

Eligibility Renal Cell Carcinoma NCT00831857

- 29/09/18 - 1 modulo, 1 ItemGroup, 13 elementi, 1 linguaggio
ItemGroup: Inclusion Criteria
VEGF Imaging in Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00831857

Eligibility Renal Cell Carcinoma NCT00631371

- 29/09/18 - 1 modulo, 2 itemgroups, 8 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT00631371

Eligibility Renal Cell Carcinoma NCT00417677

- 28/09/18 - 1 modulo, 1 ItemGroup, 19 elementi, 1 linguaggio
ItemGroup: Criteria
A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00417677

Eligibility Kidney Cancer NCT00365768

- 03/10/16 - 1 modulo, 2 itemgroups, 9 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00365768

Eligibility Kidney Tumor NCT01967407 DRKS00004266

- 23/07/17 - 1 modulo, 2 itemgroups, 33 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Responsible Party: Johann J. Wendler, MD, Dr. med., University of Magdeburg ClinicalTrials.gov Identifier: NCT01967407 History of Changes Other Study ID Numbers: DE-UKMD-URO-001 DRKS00004266 ( Other Identifier: DRKS (German Clinical Trials Registry) ) U1111-1140-0415 ( Other Identifier: Universal Trial Number (UTN) ) DRKS00004266 ( Other Identifier: Internat. Clinical Trials Registry Platform ICTRP, WHO ) EUDAMED-No.: CIV-12-04-006021 ( Other Identifier: BfArM, German Federal Inst. for Drugs & Medical Devices ) 00020520 ( Other Identifier: DIMDI, German Inst. for Med. Documentation & Information ) Study First Received: October 15, 2013 Last Updated: November 18, 2014

Eligibility Renal Cell Carcinoma NCT00610389

- 20/09/21 - 1 modulo, 2 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00610389

Eligibility Renal Cell Carcinoma NCT00448721

- 28/09/18 - 1 modulo, 2 itemgroups, 15 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00448721

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial